May 4, 2020 / 10:06 PM / a month ago

BRIEF-Aduro Biotech Q1 Loss Per Share $0.09

Aduro Biotech Inc:

* ADURO BIOTECH PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS

* Q1 REVENUE ESTIMATE $10.5 MILLION — REFINITIV IBES DATA

* Q1 EARNINGS PER SHARE ESTIMATE $-0.14 — REFINITIV IBES DATA

* REVENUE WAS $14.0 MILLION FOR Q1 OF 2020 COMPARED TO $3.9 MILLION FOR SAME PERIOD IN 2019

* ADURO BIOTECH - ENDED Q1 WITH CASH POSITION OF $205.9 MILLION, WHICH ENABLES CO TO CONTINUE SUPPORTING DEVELOPMENT OF STING AND APRIL PROGRAMS INTO 2023

* ADURO BIOTECH - CURRENTLY FOCUSED ON ACTIVATING CLINICAL TRIAL SITES & ENROLLING PATIENTS FOR PART 3 OF PHASE 1 STUDY OF BION-1301 IN IGA NEPHROPATHY

* ADURO BIOTECH - EXPECT TO PRESENT INTERIM DATA FOR ONGOING PHASE 2 CLINICAL TRIAL EVALUATING ADU-S100 AND PEMBROLIZUMAB IN SCCHN IN SECOND HALF 2020 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below